ETF Monitors

Weekly ETF Monitor for week ending 11 December 2020

This week's highlights

  • ETFS S&P Biotech ETF (CURE) was the top-performing unleveraged fund last week as COVID-19 vaccine rollouts commenced. Domestic resource sector funds (OZR and QRE) were also amongst the top performers. China-related funds CNEW, CETF and IZZ were the poorest performing equity funds, while UK and European funds F100 and ESTX also saw negative weeks.

  • Precious metals declined last week with gold (GOLD), which dropped 1.4%, being the best performer. Platinum fund ETPMPT dropped 6.1% and was the week’s overall poorest performing ETF. Pound sterling fund POU was also amongst the worst performers as Brexit concerns escalated.

  • Total reported flows into domestically domiciled ETFs were $449m, while outflows totalled $26m. Domestic equity funds STW and IOZ saw the biggest inflows for the week, followed by currency hedged S&P 500 fund IHVV and a range of other, mostly equity, funds. Short equity funds BBOZ, BEAR and BBUS saw the bulk of the week’s outflows.

  • VAS was the most traded fund for the week, followed by IOZ and STW. IHVV and FAIR saw above average volumes.

  • ETFS Ultra Short Nasdaq 100 Hedge Fund (SNAS) was the week’s top performing fund, returning 3.2%. SNAS uses a portfolio of short Nasdaq-100 futures to gain an inverse exposure to the Nasdaq-100 Index, which is actively managed at between -200% and -275% of the fund’s net assets. SNAS is also currency hedged to reduce the impact of any moves in the AUD/USD exchange rate.